Cost-effectiveness analysis of 9-valent human papillomavirus vaccine combined with screening for cervical cancer in Japan.

ABSTRACT:

Objective

In Japan, the current coverage rate of human papillomavirus (HPV) vaccination is only 30%, and the rate of biennial cervical screening is 40%. The Japanese Government has attempted to increase the coverage of HPV vaccination and cervical screening. We analyzed the cost-effectiveness of the 9-valent HPV vaccine and cervical screening in Japan.

Methods

A yearly cycle Markov model with 15 health states was created to evaluate the cost-effectiveness of the 9-valent HPV vaccination and cervical screening in women aged 12-75 years. We considered four scenarios: 30% coverage of vaccination with 40% coverage of biennial screening (Scenario 1 representing the current Japanese situation), 70% (the highest proportion in 2013 in Japan) and 90% coverage of vaccination with 40%

SUBMITTER: Takamoto N 

PROVIDER: S-EPMC12011068 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature